Abstract
Objective To investigate the effects of low dose flutamide (250 mg/d) on hirsutism score and hormone levels in women with hirsutism.
Design Nonrandomized, prospective clinical trial.
Patients Forty-one patients with moderate-severe hirsutism were included in the study.
Intervention Hirsute patients received 250 mg/d flutamide for a period of 6 months.
Main outcome measures Hirsutism score, FSH, LH, E2, total T, free T, androstenedione, DHEAS, PRL, 17-hydroxyprogesterone, and sex hormone-binding globulin levels were detected in all the patients before treatment and every 3 months during treatment.
Results Treatment with the antiandrogen flutamide resulted in a particularly rapid and marked decrease in the hirsutism score, which decreased from 17.48 +/- 5.35 to 5.07 +/- 2.89 after 6 months. No significant changes in the levels of hormone and no serious side effects were observed in the study.
Conclusion The low-dose flutamide, 250 mg/d, is a cost-effective drug in the treatment of hirsutism. Low-dose flutamide may be used in place of high-dose flutamide, 500 to 750 mg/d.
flutamide treatment for hirsutism, low dose antiandrogen hirsutism outcomes, flutamide 250 mg hirsutism score, androgen blocker for excess hair growth, hirsutism treatment pharmacological, pcos hirsutism management with flutamide, hyperandrogenism treatment options, antiandrogen therapy unwanted facial hair, cost-effective hirsutism medication
Keywords
Adolescent, Adult, Androgen Antagonists/therapeutic Use, Androstenedione/blood, Dose-Response Relationship, Drug, Estrogens/blood, Female, Flutamide/therapeutic Use, Follicle Stimulating Hormone/blood, Hirsutism/blood/drug Therapy, Humans, Luteinizing Hormone/blood, Progesterone/blood, Prospective Studies, Testosterone/blood, Androgen Antagonists, Estrogens, Testosterone, Androstenedione, Progesterone, Flutamide, Luteinizing Hormone, Follicle Stimulating Hormone,